Home
/
Amylyx Pharmaceuticals, Inc.
/
Financials
/
Quarterly
Amylyx Pharmaceuticals, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Amylyx Pharmaceuticals, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2022
Sep 30, 2022
$345.0K
Nov 10, 2022
Q3
2022
Sep 30, 2021
$285.0K
Nov 10, 2022
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$0
Nov 6, 2025
Q2
2025
Jun 30, 2025
$0
Aug 7, 2025
Q1
2025
Mar 31, 2025
$0
May 8, 2025
Q3
2025
Sep 30, 2024
$416.0K
Nov 6, 2025
Q2
2025
Jun 30, 2024
($1.02M)
Aug 7, 2025
Q1
2025
Mar 31, 2024
$88.64M
May 8, 2025
Q3
2024
Sep 30, 2023
$102.69M
Nov 7, 2024
Q2
2024
Jun 30, 2023
$98.22M
Aug 8, 2024
Q1
2024
Mar 31, 2023
$71.43M
May 9, 2024
Q3
2023
Sep 30, 2022
$345.0K
Nov 9, 2023
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($34.39M)
Nov 6, 2025
Q2
2025
Jun 30, 2025
($41.44M)
Aug 7, 2025
Q3
2025
Jun 30, 2025
($41.44M)
Nov 6, 2025
Q3
2025
Mar 31, 2025
($35.91M)
Nov 6, 2025
Q1
2025
Mar 31, 2025
($35.91M)
May 8, 2025
Q2
2025
Mar 31, 2025
($35.91M)
Aug 7, 2025
Q3
2025
Sep 30, 2024
($72.70M)
Nov 6, 2025
Q2
2025
Jun 30, 2024
($72.70M)
Aug 7, 2025
Q3
2025
Jun 30, 2024
($72.70M)
Nov 6, 2025
Q2
2025
Mar 31, 2024
($118.79M)
Aug 7, 2025
Q3
2025
Mar 31, 2024
($118.79M)
Nov 6, 2025
Q1
2025
Mar 31, 2024
($118.79M)
May 8, 2025
Q3
2024
Sep 30, 2023
$20.89M
Nov 7, 2024
Q2
2024
Jun 30, 2023
$22.07M
Aug 8, 2024
Q3
2024
Jun 30, 2023
$22.07M
Nov 7, 2024
Q3
2024
Mar 31, 2023
$1.57M
Nov 7, 2024
Q1
2024
Mar 31, 2023
$1.57M
May 9, 2024
Q2
2024
Mar 31, 2023
$1.57M
Aug 8, 2024
Q3
2023
Sep 30, 2022
($53.76M)
Nov 9, 2023
Q2
2023
Jun 30, 2022
($54.07M)
Aug 10, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($36.03M)
Nov 6, 2025
Q2
2025
Jun 30, 2025
($42.86M)
Aug 7, 2025
Q1
2025
Mar 31, 2025
($37.80M)
May 8, 2025
Q3
2025
Sep 30, 2024
($75.66M)
Nov 6, 2025
Q2
2025
Jun 30, 2024
($76.29M)
Aug 7, 2025
Q1
2025
Mar 31, 2024
($122.13M)
May 8, 2025
Q3
2024
Sep 30, 2023
$18.72M
Nov 7, 2024
Q2
2024
Jun 30, 2023
$20.20M
Aug 8, 2024
Q1
2024
Mar 31, 2023
($2.05M)
May 9, 2024
Q3
2023
Sep 30, 2022
($54.68M)
Nov 9, 2023
Q2
2023
Jun 30, 2022
($54.25M)
Aug 10, 2023
Q1
2023
Mar 31, 2022
($47.81M)
May 11, 2023
Q3
2022
Sep 30, 2021
($22.92M)
Nov 10, 2022
Q2
2022
Jun 30, 2021
($18.59M)
Aug 11, 2022
Q1
2022
Mar 31, 2021
($12.87M)
May 12, 2022